Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results

Milestone Pharmaceuticals (NASDAQ:MIST) announced its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05, Zacks reports.

Milestone Pharmaceuticals Stock Up 1.0%

Shares of MIST stock opened at $1.93 on Thursday. The stock has a fifty day moving average of $1.93 and a 200 day moving average of $1.73. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $2.75. The firm has a market capitalization of $164.03 million, a price-to-earnings ratio of -2.30 and a beta of 0.54.

Institutional Trading of Milestone Pharmaceuticals

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. Creative Planning grew its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 74.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 23,410 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Creative Planning’s holdings in Milestone Pharmaceuticals were worth $45,000 at the end of the most recent quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on MIST shares. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo & Company started coverage on shares of Milestone Pharmaceuticals in a report on Thursday, September 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Hold” and an average target price of $4.50.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.